Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.
The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:
- KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
- KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
- KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
- KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.
Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.
Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.
For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.
Kymera Therapeutics reported significant progress in its clinical trials and financial results for 2021. The company completed dose escalation in the KT-474 Phase 1 trial, demonstrating near complete IRAK4 degradation and a favorable safety profile. It has initiated Phase 1 studies for KT-333 and KT-413 with clear INDs. Kymera's cash balance at year-end was approximately $568 million, ensuring operational funding into 2025. Notable milestones include the expected IND filing for KT-253 in 2H22 and ongoing partnerships to enhance its discovery platform.
Kymera Therapeutics (NASDAQ: KYMR), based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company specializing in targeted protein degradation. The company will participate in several upcoming virtual investor conferences, featuring key executives discussing advancements in their drug discovery platform. Notable events include a fireside chat at the B. Riley Securities Oncology Investor Conference on January 28 and a panel on the promise of protein degradation at the BIO CEO and Investor Conference on February 16. Archived webcasts will be available on their website.
Kymera Therapeutics (NASDAQ: KYMR) has appointed Dr. John Maraganore to its Board of Directors, bringing extensive experience as the founding CEO of Alnylam Pharmaceuticals. Dr. Maraganore is recognized for his leadership in RNA therapeutics, having built Alnylam into a $25 billion company. He expressed excitement about Kymera's innovative approach to targeted protein degradation, highlighting its unique pipeline and commitment to advancing new therapeutic programs across immune-inflammatory and oncology indications. Kymera aims to become a leader in the emerging field of degrader medicines.
Kymera Therapeutics (NASDAQ: KYMR) announces 2022 R&D objectives, focusing on advancing its therapeutic pipeline aimed at immune-inflammatory diseases and oncology. The company has completed dose escalation for its KT-474 Phase 1 trial in healthy volunteers and plans to start patient dosing soon. Key programs include IRAK4, IRAKIMiD, and STAT3, with proof-of-biology and mechanism data forthcoming. Additionally, an IND filing for the MDM2 degrader program, KT-253, is expected in the second half of 2022. Overall, Kymera maintains a strong financial position to support its growth ambitions.
Kymera Therapeutics (NASDAQ: KYMR) announced its participation in the virtual 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:00 a.m. ET. Nello Mainolfi, PhD, will present the company’s progress and upcoming milestones for 2022. A live webcast will be available on the company’s website, with an archived recording accessible for 30 days. Founded in 2016, Kymera focuses on developing targeted protein degradation therapies to address challenging diseases. The company aims to lead in this innovative biopharmaceutical domain.
Kymera Therapeutics (NASDAQ: KYMR) announced significant clinical advancements during its first R&D Day. Notable highlights include the successful Phase 1 trial of KT-474, demonstrating near complete IRAK4 degradation and favorable safety in healthy volunteers. The introduction of KT-253, a new MDM2 degrader, targets multiple tumors, with an IND filing expected in 2022. Kymera aims for a disease-agnostic pipeline and plans to initiate new clinical trials in 2022, reinforcing its commitment to transforming patient care through targeted protein degradation.
Kymera Therapeutics (NASDAQ: KYMR) presented promising preclinical data on its first-in-class STAT3 degrader, KT-333, at the 63rd American Society of Hematology Annual Meeting. KT-333 demonstrated over 90% STAT3 knockdown in ALK+ anaplastic large cell lymphoma (ALCL) models, leading to significant tumor regression. The studies suggest the potential for KT-333 in combination with immune checkpoint inhibitors in solid tumors. A Phase 1 trial is set to start, focusing on hematologic and solid cancers. The findings may help identify patients likely to respond to STAT3 degraders.
Kymera Therapeutics (NASDAQ: KYMR) has appointed Vijay Sabesan as Senior Vice President of Technical Operations. With over 25 years in the pharmaceutical industry, Sabesan has extensive experience in drug development, regulatory interactions, and commercial approvals. He aims to strengthen Kymera's operational capabilities as the company advances its pipeline, which includes three clinical stage programs. Kymera is focused on targeted protein degradation to address significant disease targets and is striving to become a fully integrated global biotech company.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced the FDA's clearance of its Investigational New Drug application for KT-413, a targeted protein degrader aimed at treating relapsed/refractory B cell lymphomas. This represents the company's third IND clearance in 2021 and advances their clinical pipeline. KT-413 targets MYD88-mutant diffuse large B-cell lymphoma by degrading IRAK4 and IMiD substrates to enhance anti-tumor activity. Kymera aims to revolutionize treatment through its innovative Pegasus™ platform.
Kymera Therapeutics (NASDAQ: KYMR) will host a virtual R&D Day for analysts and investors on December 16, 2021, from 8:30 a.m. to 11:00 a.m. ET. This event will feature presentations from key leadership, including CEO Nello Mainolfi and Chief Medical Officer Jared Gollob. Attendees will receive updates on Kymera’s lead programs, including KT-474 Phase 1 trial data, IRAKIMiD (KT-413), STAT3 (KT-333), and new clinical pathways. The company aims to advance targeted protein degradation therapies to treat significant diseases.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
What is Kymera Therapeutics' main focus?
What is the Pegasus platform?
What are some key drugs in Kymera's pipeline?
What diseases is Kymera targeting?
What recent achievements has Kymera made?
How does Kymera's technology differ from conventional therapies?
Who are Kymera's partners?
Where is Kymera Therapeutics headquartered?
How is Kymera funded?
Where can I find more information about Kymera?
